...
首页> 外文期刊>Journal of Bioscience and Bioengineering >Strategy for erythroid differentiation in &ITex vivo&IT cultures: Lentiviral genetic modification of human hematopoietic stem cells with erythropoietin gene
【24h】

Strategy for erythroid differentiation in &ITex vivo&IT cultures: Lentiviral genetic modification of human hematopoietic stem cells with erythropoietin gene

机译:红细胞分化的策略和ITEX体内&IT文化:促红细胞生成素基因的慢病毒遗传修饰人造血干细胞

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

If cultured in appropriate conditions, such as supplementing culture media with costly cytokines and growth factors, hematopoietic stem/progenitor cells (HSPCs) from different origins have shown to be an adequate source of erythroid cells. This requirement turns erythroid cells production into a complicated process to be scaled-up for future applications. The aim of our work was to genetically modify HSPCs with human erythropoietin (hEPO) sequence by lentiviral transgenesis in order for cells to secrete the hormone into the culture medium. Initially, we evaluated erythroid differentiation in colony forming units (CFU) assays and further analyzed cell expansion and erythroid differentiation throughout time in suspension cultures by flow cytometry and May-Grunwald-Giemsa staining. Additionally, we studied hEPO production and its isoforms profile. The different assessment approaches demonstrated erythroid differentiation,which was attributed to the hEPO secreted by the HSPCs. Our data demonstrate that it is possible to develop culture systems in which recombinant HSPCs are self-suppliers of hEPO. This feature makes our strategy attractive to be applied in biotechnological production processes of erythroid cells that are currently under development. (C) 2017, The Society for Biotechnology, Japan. All rights reserved.
机译:如果在适当的条件下培养,例如用昂贵的细胞因子和生长因子补充培养基,来自不同起源的造血茎/祖细胞(Hspcs)已显示是红细胞的足够来源。该要求将红细胞生成转化为复杂的过程,以缩小未来的应用。我们的作品的目的是通过慢病毒转基因将HSPC与人促红细胞生成素(HEPO)序列进行转基因,以便细胞将激素分泌到培养基中。最初,我们在菌落形成单元(CFU)测定中评估了红细胞分化,并通过流式细胞术和May-Grunwald-Giemsa染色进一步分析了整个时间悬浮培养的细胞膨胀和红细胞分化。此外,我们研究了HEPO生产及其同种型型材。不同的评估方法显示红细胞分化,其归因于HSPCS分泌的HEPO。我们的数据表明,可以开发培养系统,其中重组Hspc是HEPO的自供应商。此功能使我们的策略适用于目前正在开发的红细胞细胞的生物技术生产过程中。 (c)2017年,日本生物技术协会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号